| abstract |
The invention belongs to the field of biomedicine and discloses the use of FAM83A, KPNA2, KRT6A and LDHA gene combination as a lung adenocarcinoma biological marker. The invention also discloses the use of the substances for detecting FAM83A, KPNA2, KRT6A and LDHA in the preparation of the kit. The invention uses FAM83A, KPNA2, KRT6A and LDHA as biomarkers for combined detection, provides an ideal expression profile analysis strategy, and a new combined biomarker kit for lung adenocarcinoma risk assessment and prognosis analysis, which can It is effectively used for the diagnosis or prognosis evaluation of lung adenocarcinoma, and has a good clinical application prospect. |